Related references
Note: Only part of the references are listed.Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
Matthew J. Budoff et al.
CARDIOVASCULAR RESEARCH (2021)
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
Brian Olshansky et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies
Patrick R. Lawler et al.
EUROPEAN HEART JOURNAL (2020)
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
Samuel C. R. Sherratt et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2020)
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
William E. Boden et al.
EUROPEAN HEART JOURNAL (2020)
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
R. Preston Mason et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Response by Bhatt et al to Letter Regarding Article, REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Deepak L. Bhatt et al.
CIRCULATION (2020)
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Matthew J. Budoff et al.
EUROPEAN HEART JOURNAL (2020)
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Fabien Picard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT!
Deepak L. Bhatt
EUROPEAN HEART JOURNAL (2019)
Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Philippe Gabriel Steg et al.
CIRCULATION (2019)
REPLY: Ischemic Event Reduction and Triglycerides
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
R. Preston Mason
CURRENT ATHEROSCLEROSIS REPORTS (2019)
Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
Wenjun Fan et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
JoAnn E. Manson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FISHing for the Miracle of Eicosapentaenoic Acid
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl
Lingtak-Neander Chan
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction
Samuel C. R. Sherratt et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2018)
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Om P. Ganda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks Meta-analysis of 10 Trials Involving 77 917 Individuals
Theingi Aung et al.
JAMA CARDIOLOGY (2018)
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J. Nicholls et al.
CLINICAL CARDIOLOGY (2018)
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus
Louise Bowman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Trends in Total Cholesterol, Triglycerides, and Low-Density Lipoprotein in US Adults, 1999-2014
Asher Rosinger et al.
JAMA CARDIOLOGY (2017)
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Deepak L. Bhatt et al.
CLINICAL CARDIOLOGY (2017)
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease
K. H. Bonaa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Marja-Riitta Taskinen et al.
ATHEROSCLEROSIS (2015)
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction
Dion Stub et al.
CIRCULATION (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Relationship of Lipoproteins to Cardiovascular Events The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
John R. Guyton et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
Willem J. M. Dewilde et al.
LANCET (2013)
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Rena Wing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Jackie Bosch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Yasushi Saito et al.
ATHEROSCLEROSIS (2008)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
Anne B. Rossebo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
Mitsuhiro Yokoyama et al.
LANCET (2007)
Coronary intervention for persistent occlusion after myocardial infarction
Judith S. Hochman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
